通过真菌生物转化增强2'-基黄的物理化学特性和生物活性
Jie Ren1, Kyle Jackson1, Caleb Don Barton1
1Department of Biological Engineering, Utah State University, 4105 Old Main Hill, Logan, UT 84322-4105, USA.
Journal of bioscience and bioengineering
|June 10, 2024
概括
的生物转化增强了黄的水溶性和生物活性. 新的衍生品显示出更好的抗氧化和抗癌特性,克服了人类健康益处的自然限制.
科学领域:
- 自然产品化学 自然产品化学
- 微生物生物技术 微生物生物技术
- 药用化学 医学化学
背景情况:
- 黄酸具有多样化的生物活性,但其水溶性和生物可用性较差.
- 这些局限性阻碍了它们在人类中充分发挥治疗潜力的实现.
研究的目的:
- 使用微生物转化生物合成新型黄类衍生物.
- 为了增强黄的水溶性和生物活性.
- 评估改性化合物的抗氧化和抗癌特性.
主要方法:
- 使用Beauveria bassianaATCC 7159.9进行2'-基黄的微生物转化.
- 使用1D和2DNMR光谱学的产品的结构特征.
- 对水溶性,抗氧化活性 (DPPH测定) 和抗癌活性对抗 Glioblastoma 33 癌症干细胞的评估.
主要成果:
- 生物合成了五种黄类衍生物;四种是新型结构.
- 与基质相比,水溶性增加了30-280倍.
- 化合物1和2显示了增强的DPPH激素清除活性.
- 化合物5对质母细胞瘤33细胞显著改善了抗癌活性.
结论:
- 菌生物转化是一种有效的策略,可以改善黄类的水溶性和生物活性.
- 新型黄类衍生物具有增强的治疗潜力.
- 这种方法为开发新的基于黄类药物的新药提供了有希望的途径.
相关概念视频
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
233
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
233
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Phase II Reactions: Glucuronidation
381
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
381
Phase I Oxidative Reactions: Overview
264
Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...
264
Factors Affecting Drug Biotransformation: Biological
142
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
142


